TXG

10x Genomics, Inc.

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.

10x Genomics, Inc. (TXG) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (D). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
D
Factor Score 1.5 / 5.0
Growth
C
Factor Score 2.5 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 671.4
EV / EBITDA -269.9
Rev Growth YoY 1.1%
Gross Margin 72.0%
Price Return 3M 0.3%
Price Return 12M 248.7%
Catalyst Signal 0.00
Market Cap $7.7B
TTM Revenue $618.6M
Price / Sales 12.4
ROE -8.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D (1.5) C (2.5) B- (2.9) B (3.4) C+ (2.6) C+ (2.6)
2026-11-08 D (1.5) C (2.5) B- (2.9) B (3.4) C+ (2.6) C+ (2.6)
2026-11-01 D (1.5) C+ (2.8) B- (2.9) B (3.4) C+ (2.7) C+ (2.7)
2026-10-25 D (1.5) C+ (2.8) B- (2.9) B (3.4) C+ (2.6) C+ (2.6)
2026-10-18 D (1.5) C+ (2.8) B- (2.9) B (3.4) C+ (2.6) C+ (2.6)
Page 1 of 7